Zhou Quan, Zuo Man-Zhen, He Ze, Li Hai-Rong, Li Wei
Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China.
Int J Biol Markers. 2018 Apr 1:1724600818766500. doi: 10.1177/1724600818766500.
Circulating microRNAs (miRNAs) are proposed as promising non-invasive diagnostic biomarkers for many cancers. However, the diagnostic value of circulating miRNAs in ovarian cancer is inconsistent in different studies. Thus we performed this meta-analysis to systematically evaluate the diagnostic value of circulating miRNAs in ovarian cancer.
Eligible studies that were published prior to 30 June 2017 were searched from the PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure. All analyses were performed using STATA 12.0 software. A bivariate regression was used to calculate pooled diagnostic accuracy estimates.
A total of 36 studies from 16 publications were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating miRNAs for ovarian cancer diagnosis were 0.76 (95% confidence intervals (CI): 0.69, 0.81), 0.81 (95% CI 0.74, 0.87), 4.00 (95% CI 2.70, 5.30), 0.30(95% CI 0.24, 0.37) and 13.00 (95% CI 9.00, 19.00), respectively. The area under the summary receiver operating characteristic curve was 0.85 (95% CI 0.82, 0.88). Subgroup analyses showed that multiple miRNA assays yielded better diagnostic characteristics than a single miRNA assay, and plasma miRNAs were better than serum miRNAs for ovarian cancer detection.
Circulating miRNAs, especially the combination of multiple circulating miRNAs, are promising biomarkers for the diagnosis of ovarian cancer. However, further large-scale prospective studies are necessary to validate the applicability of the miRNAs in the early detection of ovarian cancer.
循环微RNA（miRNA）被认为是许多癌症有前景的非侵入性诊断生物标志物。然而，不同研究中循环miRNA在卵巢癌中的诊断价值并不一致。因此，我们进行了这项荟萃分析，以系统评估循环miRNA在卵巢癌中的诊断价值。
从PubMed、EMBASE、Cochrane图书馆和中国知网检索2017年6月30日前发表的符合条件的研究。所有分析均使用STATA 12.0软件进行。采用双变量回归计算合并诊断准确性估计值。
本荟萃分析共纳入16篇出版物中的36项研究。循环miRNA用于卵巢癌诊断的合并敏感性、特异性、阳性似然比、阴性似然比和诊断比值比分别为0.76（95%置信区间（CI）：0.69，0.81）、0.81（95%CI 0.74，0.87）、4.00（95%CI 2.70，5.30）、0.30（95%CI 0.24，0.37）和13.00（95%CI 9.00，19.00）。汇总受试者工作特征曲线下面积为0.85（95%CI 0.82，0.88）。亚组分析表明，多种miRNA检测方法比单一miRNA检测方法具有更好的诊断特征，血浆miRNA在检测卵巢癌方面优于血清miRNA。
循环miRNA，尤其是多种循环miRNA的组合，是卵巢癌诊断有前景的生物标志物。然而，需要进一步的大规模前瞻性研究来验证miRNA在卵巢癌早期检测中的适用性。
